Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation
Non‐small cell lung cancer (NSCLC) affects 10–50% of patients with epidermal growth factor receptor (EGFR) mutations. Osimertinib is a third‐generation EGFR tyrosine kinase inhibitor (TKI) that radically changes the outcome of patients with tumors bearing EGFR sensitizing or EGFR T790M resistance mu...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Wiley
2025-05-01
|
| Ráidu: | FEBS Open Bio |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1002/2211-5463.13970 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
